Puma Biotechnology $PBYI CEO Alan Auerbach just beat some heavy odds weighing against neratinib.
After appealing a negative opinion adopted by the Committee for Medicinal Products for Human Use, the EMA group has reversed course and is now recommending an approval.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,